Davidson Alan, Hartley Patricia, Desai Farieda, Daubenton John, Rode Heinz, Millar Alastair
Haematology-Oncology Service, Red Cross Children's Hospital, School of Child and Adolescent Health, University of Cape Town, Cape Town, South Africa.
Pediatr Blood Cancer. 2006 Apr;46(4):465-71. doi: 10.1002/pbc.20388.
In Africa, Wilms tumour frequently presents with advanced disease. This study reports our results over 25 years using the National Wilms Tumour Study Group (NWTSG) approach of primary surgery followed by chemotherapy.
A retrospective analysis was performed on all patients diagnosed with unilateral Wilms tumour between January 1979 and December 2003.
The records of 188 children with newly diagnosed Wilms tumour were examined. Of these 57 (30.3%) were stage I, 33 (17.6%) were stage II, 60 (31.9%) were stage III and 38 (20.2%) were stage IV. Twenty-four patients (12.8%) had unfavourable histology (UFH). The estimated 5-year overall survival (OS) for the whole group was 80.5% (84.8% for favourable histology (FH) and 51.6% for UFH). Among those with FH, estimated 5-year OS was 94.4% for stage I, 96.2% for stage II, 84.9% for stage III and 54.2% for stage IV. There was no difference in OS between those FH stage III tumours that were operable and those deemed inoperable. Intra-operative spillage was uncommon (8%), and did not increase local relapse rate.
National Wilms Tumour Study Group protocols employed in an African setting with highly competent and experienced surgical care, produced results for non-metastatic FH Wilms tumour comparable to those of the NWTSG.
在非洲,肾母细胞瘤常表现为晚期疾病。本研究报告了我们25年来采用国家肾母细胞瘤研究组(NWTSG)的方法,即先进行原发手术再进行化疗的结果。
对1979年1月至2003年12月期间所有诊断为单侧肾母细胞瘤的患者进行回顾性分析。
检查了188例新诊断为肾母细胞瘤患儿的记录。其中57例(30.3%)为I期,33例(17.6%)为II期,60例(31.9%)为III期,38例(20.2%)为IV期。24例患者(12.8%)有不良组织学类型(UFH)。整个组的估计5年总生存率(OS)为80.5%(良好组织学类型(FH)为84.8%,UFH为51.6%)。在FH患者中,I期的估计5年OS为94.4%,II期为96.2%,III期为84.9%,IV期为54.2%。FH III期肿瘤中可手术切除的与不可手术切除的患者在OS方面无差异。术中溢出情况不常见(8%),且未增加局部复发率。
在非洲环境中采用国家肾母细胞瘤研究组方案,并具备高度胜任且经验丰富的外科护理,对于非转移性FH肾母细胞瘤所产生的结果可与NWTSG相媲美。